SI1021186T1 - Purinski inhibitorji ciklinsko odvisne kinaze 2 in IkappaB-alfa - Google Patents

Purinski inhibitorji ciklinsko odvisne kinaze 2 in IkappaB-alfa

Info

Publication number
SI1021186T1
SI1021186T1 SI9730717T SI9730717T SI1021186T1 SI 1021186 T1 SI1021186 T1 SI 1021186T1 SI 9730717 T SI9730717 T SI 9730717T SI 9730717 T SI9730717 T SI 9730717T SI 1021186 T1 SI1021186 T1 SI 1021186T1
Authority
SI
Slovenia
Prior art keywords
alkyl
substituted
cycloalkyl
benzylamino
cycloheteroalkyl
Prior art date
Application number
SI9730717T
Other languages
English (en)
Slovenian (sl)
Inventor
Robert T Lum
Cheri Lynn Blum
Richard Mackman
Michael M Wick
Steven R Schow
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of SI1021186T1 publication Critical patent/SI1021186T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SI9730717T 1996-08-02 1997-08-01 Purinski inhibitorji ciklinsko odvisne kinaze 2 in IkappaB-alfa SI1021186T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/692,012 US5866702A (en) 1996-08-02 1996-08-02 Purine inhibitors of cyclin dependent kinase 2
PCT/US1997/013386 WO1998005335A1 (en) 1996-08-02 1997-08-01 PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IλB-$g(a)
EP97936297A EP1021186B1 (en) 1996-08-02 1997-08-01 PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IkappaB-alpha

Publications (1)

Publication Number Publication Date
SI1021186T1 true SI1021186T1 (sl) 2005-12-31

Family

ID=24778922

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9730717T SI1021186T1 (sl) 1996-08-02 1997-08-01 Purinski inhibitorji ciklinsko odvisne kinaze 2 in IkappaB-alfa

Country Status (25)

Country Link
US (1) US5866702A (Direct)
EP (1) EP1021186B1 (Direct)
JP (1) JP2000515550A (Direct)
KR (1) KR100403336B1 (Direct)
CN (1) CN1161356C (Direct)
AT (1) ATE298572T1 (Direct)
AU (1) AU731778B2 (Direct)
BR (1) BR9710801A (Direct)
CA (1) CA2262454C (Direct)
CZ (1) CZ299381B6 (Direct)
DE (1) DE69733674T2 (Direct)
DK (1) DK1021186T3 (Direct)
ES (1) ES2242981T3 (Direct)
GE (1) GEP20022786B (Direct)
HU (1) HUP9902414A3 (Direct)
IL (1) IL128323A (Direct)
NO (1) NO323775B1 (Direct)
NZ (1) NZ334061A (Direct)
PL (1) PL189775B1 (Direct)
PT (1) PT1021186E (Direct)
RU (1) RU2220968C2 (Direct)
SI (1) SI1021186T1 (Direct)
TR (1) TR199900683T2 (Direct)
UA (1) UA71890C2 (Direct)
WO (1) WO1998005335A1 (Direct)

Families Citing this family (150)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0874846B1 (en) * 1995-11-01 2003-04-02 Novartis AG Purine derivatives and processes for their preparation
FR2741881B1 (fr) * 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
US6790958B2 (en) * 1996-08-02 2004-09-14 Robert T. Lum Purine inhibitors of cyclin dependent kinase 2 & IKBA
AU4920397A (en) * 1996-10-11 1998-05-11 Chiron Corporation Purine inhibitors of glycogen synthase kinase 3 (gsk3)
DE19653646A1 (de) * 1996-12-20 1998-06-25 Hoechst Ag Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung
ES2253821T3 (es) * 1997-07-12 2006-06-01 Cancer Research Technology Limited Derivados de purina inhibidores de quinasa que depende de ciclina.
US6255485B1 (en) * 1997-08-07 2001-07-03 The Regents Of The University Of California Purine inhibitors of protein kinases, G proteins and polymerases
US6573044B1 (en) * 1997-08-07 2003-06-03 The Regents Of The University Of California Methods of using chemical libraries to search for new kinase inhibitors
ATE260989T1 (de) * 1997-12-19 2004-03-15 Affymetrix Inc Erkenntnisse der genomforschung für die suche nach neuartigen wirkstoffen
EP1418244A1 (en) * 1997-12-19 2004-05-12 Affymetrix, Inc. Exploiting genomics in the search for new drugs
US6642231B2 (en) * 1998-02-26 2003-11-04 Aventis Pharmaceuticals Inc. 6,9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
US6479487B1 (en) 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
US6413974B1 (en) 1998-02-26 2002-07-02 Aventis Pharmaceuticals Inc. 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
US6221873B1 (en) 1998-03-04 2001-04-24 Institute Of Experimental Botany Of The Academy Of Sciences Of The Czech Republic Cyclin dependent kinase inhibitor
US6703395B2 (en) 1998-03-04 2004-03-09 Institute Of Experimental Botany Of The Academy Of Sciences Of The Czech Republic Cyclin dependent kinase inhibitor
GB9806739D0 (en) * 1998-03-28 1998-05-27 Univ Newcastle Ventures Ltd Cyclin dependent kinase inhibitors
CA2335115C (en) * 1998-06-16 2009-01-27 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Fused azepinone cyclin dependent kinase inhibitors
US6531477B1 (en) 1998-10-13 2003-03-11 Dupont Pharmaceuticals Company 6-substituted pyrazolo [3,4-d] pyrimidin-4-ones useful as cyclin dependent kinase inhibitors
US6559152B2 (en) 1998-10-13 2003-05-06 Dupont Pharmaceuticals Company 6-substituted pyrazolo[3,4-d]pyrimidin-4-ones useful as cyclin dependent kinase inhibitors
KR100377138B1 (ko) * 1998-11-10 2003-06-12 주식회사 엘지생명과학 퓨린구조를갖는싸이클린의존키나아제저해제,그제조방법및그를함유하는항암제조성물
CZ27399A3 (cs) * 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
RU2001124352A (ru) * 1999-02-01 2004-02-20 Си Ви Терапьютикс, Инк. (Us) Пуриновые ингибиторы циклин-зависимой киназы 2 и Ikb-альфа
AU2004200192B2 (en) * 1999-02-01 2006-11-16 Gilead Palo Alto, Inc. Purine inhibitors of cyclin dependent kinase 2 and 1k-Aa
KR20000055080A (ko) * 1999-02-03 2000-09-05 성재갑 싸이클린 의존 키나아제 저해제 및 그의 제조 방법
KR100368515B1 (ko) * 1999-02-03 2003-01-24 주식회사 엘지생명과학 싸이클린 의존 키나아제 저해제 및 그의 제조 방법
GB9903762D0 (en) 1999-02-18 1999-04-14 Novartis Ag Organic compounds
US6624171B1 (en) 1999-03-04 2003-09-23 Smithkline Beecham Corporation Substituted aza-oxindole derivatives
GB9904933D0 (en) 1999-03-04 1999-04-28 Glaxo Group Ltd Compounds
US6969720B2 (en) * 1999-03-17 2005-11-29 Amr Technology, Inc. Biaryl substituted purine derivatives as potent antiproliferative agents
US6627633B2 (en) * 1999-03-17 2003-09-30 Albany Molecular Research, Inc. 6-substituted biaryl purine derivatives as potent cyclin/CDK inhibitors and antiproliferative agents
FR2793794B1 (fr) * 1999-05-21 2001-07-27 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
DE50010931D1 (de) 1999-06-23 2005-09-15 Aventis Pharma Gmbh Substituierte benzimidazole
GB9918035D0 (en) 1999-07-30 1999-09-29 Novartis Ag Organic compounds
AU2583901A (en) * 1999-12-17 2001-06-25 Ariad Pharmaceuticals, Inc. Proton pump inhibitors
US20030187261A1 (en) * 2000-01-07 2003-10-02 Libor Havlicek Purine derivatives, process for their preparation and use thereof
KR20010077073A (ko) * 2000-01-31 2001-08-17 박호군 Ｃ-２,６,９ 위치에 치환된 이소프로필퓨린 유도체 및그의 제조 방법
GB0016877D0 (en) * 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
US6861524B2 (en) 2000-10-31 2005-03-01 Aventis Pharmaceuticals Inc. Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
FR2818278B1 (fr) * 2000-12-20 2003-02-28 Sod Conseils Rech Applic Inhibiteurs de kinases dependantes des cyclines (cdk) et de la glycogene synthase kinase-3 (gsk-3)
EP1345941A1 (fr) * 2000-12-20 2003-09-24 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Inhibiteurs de kinases dependantes des cylines (cdk) et de la glycogene synthase kinase-3 (gsk-3)
FR2818642B1 (fr) * 2000-12-26 2005-07-15 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilistion
US7605175B2 (en) 2001-03-02 2009-10-20 Gpc Biotech Ag Inhibitors of cyclin-dependent kinases, compositions and uses related thereto
US6667311B2 (en) * 2001-09-11 2003-12-23 Albany Molecular Research, Inc. Nitrogen substituted biaryl purine derivatives as potent antiproliferative agents
US6812232B2 (en) 2001-09-11 2004-11-02 Amr Technology, Inc. Heterocycle substituted purine derivatives as potent antiproliferative agents
EP1578722A4 (en) * 2001-10-12 2006-09-06 Irm Llc KINASEINHIBITOR SCAFFOLD AND METHOD FOR THE PRODUCTION THEREOF
DE60218525T2 (de) 2001-12-18 2007-11-22 CV Therapeutics, Inc., Palo Alto A2a adenosinrezeptorantagonisten
CN1279984C (zh) * 2002-02-15 2006-10-18 Cv医药有限公司 用于医用装置的聚合物涂层
EA007099B1 (ru) 2002-03-13 2006-06-30 Янссен Фармацевтика Н. В. Сульфонилпроизводные в качестве ингибиторов гистон-деацетилазы
ATE521592T1 (de) 2002-03-13 2011-09-15 Janssen Pharmaceutica Nv Histone-deacetylase-inhibitoren
GB0219054D0 (en) * 2002-08-15 2002-09-25 Cyclacel Ltd New purine derivatives
GB0219052D0 (en) * 2002-08-15 2002-09-25 Cyclacel Ltd New puring derivatives
GB0219746D0 (en) * 2002-08-23 2002-10-02 Inst Of Ex Botany Ascr Azapurine derivatives
JP4664205B2 (ja) * 2002-10-15 2011-04-06 アイアールエム エルエルシー 骨形成を誘導する組成物および方法
CA2521854C (en) 2003-04-07 2011-11-01 Gpc Biotech, Inc. Inhibitors of cyclin-dependent kinases, compositions and uses related thereto
KR100573861B1 (ko) * 2003-07-18 2006-04-25 경동제약 주식회사 2-아미노-9-(2-할로게노에틸)푸린 및 그 중간체로서의 2-아미노-6,8-디클로로-9-(2-히드록시에틸)푸린의 제조방법
MXPA06001758A (es) * 2003-08-15 2006-08-11 Irm Llc Anilino purinas sustituidas en la posicion 6 utiles como inhibidores de rtk.
CN100447143C (zh) * 2003-08-15 2008-12-31 Irm责任有限公司 作为rtk抑制剂的6-取代的苯胺基嘌呤
ES2361835T3 (es) 2003-09-25 2011-06-22 Janssen Pharmaceutica Nv Derivados de purina inhibidores de la replicación del hiv.
EP1709051A1 (en) 2003-12-23 2006-10-11 GPC Biotech Inc. Inhibitors of cyclin-dependent kinases, compositions and uses related thereto
JP2006056879A (ja) * 2004-07-21 2006-03-02 Kobe Univ インスリン抵抗性の改善剤、及びそのスクリーニング方法
NZ552865A (en) 2004-07-28 2009-09-25 Janssen Pharmaceutica Nv Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
GB0419175D0 (en) * 2004-08-27 2004-09-29 Cyclacel Ltd Method of treatment and compositions
ES2403558T3 (es) 2004-08-27 2013-05-20 Cyclacel Limited Inhibidores purínicos y pirimidínicos de CDK y su uso para el tratamiento de enfermedades autoinmunitarias
DE602005007623D1 (de) 2004-10-13 2008-07-31 Hoffmann La Roche Als cdk2- und angiogenese-inhibitoren und für die behandlung von brust-, kolon-, lungen- und prostatakrebs geeignete disubstituierte pyrazolobenzodiazepine
EP1837033A4 (en) * 2004-11-12 2010-05-26 Kazuhito Tomizawa MEDICINE AGAINST DIABETES CONTAINING A Cdk5 INHIBITOR
KR100677396B1 (ko) * 2004-11-20 2007-02-02 엘지전자 주식회사 음성인식장치의 음성구간 검출방법
ES2308731T3 (es) * 2005-02-16 2008-12-01 Astrazeneca Ab Compuestos quimicos.
MX2007014297A (es) * 2005-05-16 2008-04-21 Prometic Biosciences Inc Derivados de purina y su uso para el tratamiento de enfermedades autoinmunes.
JP5321061B2 (ja) * 2005-08-11 2013-10-23 アリアド・ファーマシューティカルズ・インコーポレイテッド 不飽和複素環誘導体
CN101360494A (zh) * 2005-11-22 2009-02-04 斯克里普斯研究学院 高效埃博霉素的化学合成
DK1979326T3 (da) 2006-01-19 2013-01-07 Janssen Pharmaceutica Nv Pyridin- og pyrimidinderivater som inhibitorer af histondeacetylase
KR101452520B1 (ko) 2006-01-27 2014-10-21 샹하이 헨그루이 파마수티컬 컴퍼니 리미티드 피롤로[3,2-ｃ]피리딘-4-온 2-인돌린온 단백질 키나제 억제제
GB0606283D0 (en) * 2006-03-29 2006-05-10 Cyclacel Ltd Process
JP5486928B2 (ja) * 2007-02-26 2014-05-07 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１のサイクリックウレアおよびカルバメートインヒビター
GB0706632D0 (en) * 2007-04-04 2007-05-16 Cyclacel Ltd New purine derivatives
WO2008135232A1 (en) * 2007-05-02 2008-11-13 Riccardo Cortese Use and compositions of purine derivatives for the treatment of proliferative disorders
UA99459C2 (en) * 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
WO2008138184A1 (fr) 2007-05-14 2008-11-20 Shanghai Hengrui Pharmaceutical Co.Ltd. Dérivés de pyrrolo-azacycles, leur procédé de fabrication et leur utilisation en tant qu'inhibiteurs de protéine kinases
WO2008138232A1 (en) 2007-05-14 2008-11-20 Shanghai Hengrui Pharmaceutical Co., Ltd. Pyrrolo-nitrogenous heterocyclic derivatives, the preparation and the pharmaceutical use thereof
EP2183229B1 (en) * 2007-07-26 2012-04-18 Vitae Pharmaceuticals, Inc. Synthesis of inhibitors of 11beta-hydroxysteroid dehydrogenase type 1
FR2920776B1 (fr) * 2007-09-12 2012-09-28 Centre Nat Rech Scient Utilisation de derives de purine pour la fabrication d'un medicament
EP2215090B1 (en) * 2007-10-26 2015-03-04 F. Hoffmann-La Roche AG Purine derivatives useful as pi3 kinase inhibitors
AR069207A1 (es) * 2007-11-07 2010-01-06 Vitae Pharmaceuticals Inc Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1
WO2009075835A1 (en) 2007-12-11 2009-06-18 Vitae Pharmaceutical, Inc CYCLIC UREA INHIBITORS OF 11β-HYDROXYSTEROID DEHYDROGENASE 1
TW200934490A (en) * 2008-01-07 2009-08-16 Vitae Pharmaceuticals Inc Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1
WO2009094169A1 (en) * 2008-01-24 2009-07-30 Vitae Pharmaceuticals, Inc. Cyclic carbazate and semicarbazide inhibitors of 11beta-hydroxysteroid dehydrogenase 1
CA2714532A1 (en) * 2008-02-11 2009-08-20 Vitae Pharmaceuticals, Inc. 1,3-oxazepan-2-one and 1,3-diazepan-2-one inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1
US8598160B2 (en) * 2008-02-15 2013-12-03 Vitae Pharmaceuticals, Inc. Cycloalkyl lactame derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
WO2009117109A1 (en) * 2008-03-18 2009-09-24 Vitae Pharmaceuticals, Inc. Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1
ES2421537T3 (es) 2008-05-01 2013-09-03 Vitae Pharmaceuticals Inc Inhibidores cíclicos de la 11beta-hidroxiesteroide deshidrogenasa 1
JP5451752B2 (ja) * 2008-05-01 2014-03-26 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状インヒビター
CA2723039A1 (en) 2008-05-01 2009-11-05 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
CA2723034A1 (en) 2008-05-01 2009-11-05 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
MX2010012583A (es) * 2008-05-30 2011-02-24 Genentech Inc Compuestos inhibidores de purina pi3k y métodos de uso.
EP2315763B1 (en) 2008-07-03 2016-06-01 Glaxosmithkline LLC Benzimidazoles and related analogs as sirtuin modulators
US8846668B2 (en) 2008-07-25 2014-09-30 Vitae Pharmaceuticals, Inc. Inhibitors of 11beta-hydroxysteroid dehydrogenase 1
DK2324018T3 (da) 2008-07-25 2013-10-14 Boehringer Ingelheim Int Cykliske inhibitorer af 11 beta-hydroxysteroid dehydrogenase 1
AU2009314631B2 (en) 2008-11-12 2014-07-31 Takeda Pharmaceutical Company Limited Pyrazinopyrazines and derivatives as kinase inhibitors
CZ302122B6 (cs) * 2009-01-28 2010-10-20 Univerzita Palackého v Olomouci Substituované deriváty 6-(2-aminobenzylamino)purinu, jejich použití jako léciva a prípravky tyto slouceniny obsahující
EP2393807B1 (en) 2009-02-04 2013-08-14 Boehringer Ingelheim International GmbH Cyclic inhibitors of 11 -hydroxysteroid dehydrogenase 1
JP2012517448A (ja) 2009-02-11 2012-08-02 リアクション バイオロジー コープ． 選択的キナーゼ阻害剤
WO2010103473A1 (en) * 2009-03-10 2010-09-16 Chu De Brest Method of treatment of polycystic diseases and chronic lymphocytic leukemia
DK2414362T3 (da) * 2009-04-03 2014-09-22 Verastem Inc Pyrimidinsubstituerede purinforbindelser som kinaseinhibitorer
TW201039034A (en) * 2009-04-27 2010-11-01 Chunghwa Picture Tubes Ltd Pixel structure and the method of forming the same
US8680093B2 (en) 2009-04-30 2014-03-25 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
KR20120061771A (ko) * 2009-04-30 2012-06-13 비타이 파마슈티컬즈, 인코포레이티드 11베타-하이드록시스테로이드 탈수소효소 1의 고리형 억제제
EP2440537A1 (en) 2009-06-11 2012-04-18 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 based on the 1,3 -oxazinan- 2 -one structure
CA2766100C (en) 2009-06-29 2018-05-22 Incyte Corporation Pyrimidinones as pi3k inhibitors
WO2011002910A1 (en) 2009-07-01 2011-01-06 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
WO2011075630A1 (en) * 2009-12-18 2011-06-23 Incyte Corporation Substituted fused aryl and heteroaryl derivatives as pi3k inhibitors
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
EP2519517B1 (en) 2009-12-29 2015-03-25 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
WO2011106168A1 (en) * 2010-02-24 2011-09-01 Dcam Pharma Inc Purine compounds for treating autoimmune and demyelinating diseases
WO2011130342A1 (en) 2010-04-14 2011-10-20 Incyte Corporation FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS
EP2580320B1 (en) 2010-06-14 2018-08-01 The Scripps Research Institute Reprogramming of cells to a new fate
WO2011159760A1 (en) 2010-06-16 2011-12-22 Vitae Pharmaceuticals, Inc. Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use
WO2011163195A1 (en) 2010-06-21 2011-12-29 Incyte Corporation Fused pyrrole derivatives as pi3k inhibitors
JP5813106B2 (ja) 2010-06-25 2015-11-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 代謝障害の処置のための１１−β−ＨＳＤ１のインヒビターとしてのアザスピロヘキサノン
WO2012007493A1 (en) 2010-07-14 2012-01-19 F. Hoffmann-La Roche Ag Purine compounds selective for ρi3κ p110 delta, and methods of use
WO2012051296A2 (en) * 2010-10-12 2012-04-19 Case Western Reserve University Purine-based triazoles
EA201300522A1 (ru) 2010-11-02 2013-11-29 Бёрингер Ингельхайм Интернациональ Гмбх Фармацевтические комбинации для лечения метаболических нарушений
KR20140099556A (ko) 2010-12-16 2014-08-12 에프. 호프만-라 로슈 아게 트라이사이클릭 pi3k 억제제 화합물 및 이의 사용 방법
ES2764848T3 (es) 2010-12-20 2020-06-04 Incyte Holdings Corp N-(1-(fenilo sustituido)etilo)-9H-purina-6-aminas como inhibidores de PI3K
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
KR102131612B1 (ko) 2011-09-02 2020-07-08 인사이트 홀딩스 코포레이션 Ｐｉ３ｋ 억제제로서 헤테로시클릴아민
CA2847540C (en) 2011-09-22 2016-05-17 Pfizer Inc. Pyrrolopyrimidine and purine derivatives
US9382239B2 (en) 2011-11-17 2016-07-05 Dana-Farber Cancer Institute, Inc. Inhibitors of c-Jun-N-terminal kinase (JNK)
WO2013113762A1 (en) 2012-01-31 2013-08-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits for predicting the risk of having a cutaneous melanoma in a subject
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
EP2664619B1 (en) * 2012-05-16 2017-07-12 Manros Therapeutics Purine derivatives as tools for screening anti-Alzheimer compounds
FR3011240A1 (fr) * 2013-10-01 2015-04-03 Centre Nat Rech Scient Inhibiteurs de 5'-nucleotidases et leurs utilisations therapeutiques
AU2014337044A1 (en) 2013-10-18 2016-05-05 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
UA115388C2 (uk) 2013-11-21 2017-10-25 Пфайзер Інк. 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
CN104086551B (zh) * 2014-06-06 2016-09-21 人福医药集团股份公司 化合物及其制备方法和用途
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
WO2016105528A2 (en) 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
SI3831833T1 (sl) 2015-02-27 2023-03-31 Incyte Holdings Corporation Postopki za pripravo inhibitorja PI3K
HK1246645A1 (zh) * 2015-03-27 2018-09-14 达纳-法伯癌症研究所股份有限公司 细胞周期蛋白依赖性激酶的抑制剂
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
WO2016183060A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
JP7028766B2 (ja) 2015-09-09 2022-03-02 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼの阻害剤
CN108472298B (zh) 2015-11-24 2021-04-20 深圳阿拉丁医疗科技有限公司 选择性激酶抑制剂
EP3388432A1 (en) 2017-04-10 2018-10-17 Commissariat à l'Energie Atomique et aux Energies Alternatives Purine derivatives for use as medicament and for use in treating neurodegenerative or neuro-inflammatory disorders
IL278889B2 (en) 2018-06-01 2025-11-01 Incyte Corp Dosing regimen for the treatment of pi3k related disorders
US12187701B2 (en) 2018-06-25 2025-01-07 Dana-Farber Cancer Institute, Inc. Taire family kinase inhibitors and uses thereof
US20250101023A1 (en) * 2022-01-21 2025-03-27 Iucf-Hyu (Industry-University Cooperation Foundation Hanyang University) Heteroaryl derivative and uses thereof
CN117659016A (zh) * 2022-08-26 2024-03-08 嘉兴优博生物技术有限公司 细胞周期蛋白调节剂
AU2023393410A1 (en) 2022-12-16 2025-07-31 Astrazeneca Ab 2,6,9-trisubstituted purines
CN116813621A (zh) * 2023-06-08 2023-09-29 江南大学 9h嘌呤类化合物及其药物组合物和用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4028353A (en) * 1971-07-29 1977-06-07 Polaroid Corporation Novel chemical compounds
US4028358A (en) * 1973-09-04 1977-06-07 Liotta Charles L 6-Fluoro-9-perfluorobutyl purine
US4405781A (en) * 1981-03-02 1983-09-20 Polaroid Corporation Method for preparing salts of 6-chloropurine
NO169901C (no) * 1985-04-19 1992-08-19 Sankyo Co Analogifremgangsmaate for fremstilling av griseolsyrederivater
US4916224A (en) * 1988-01-20 1990-04-10 Regents Of The University Of Minnesota Dideoxycarbocyclic nucleosides
MY104575A (en) * 1989-12-22 1994-04-30 The Wellcome Foundation Ltd Therapeutic nucleosides.
GB9204015D0 (en) * 1992-02-25 1992-04-08 Wellcome Found Therapeutic nucleosides
FR2699176B1 (fr) * 1992-12-11 1995-03-03 Adir Nouveaux composés bicycliques de pyrimidine, leur procédé de préparation et les compositions pharmaceutiques les renfermant.
US5540934A (en) * 1994-06-22 1996-07-30 Touitou; Elka Compositions for applying active substances to or through the skin
EP0874846B1 (en) * 1995-11-01 2003-04-02 Novartis AG Purine derivatives and processes for their preparation
PL321296A1 (en) * 1995-11-14 1997-12-08 Pharmacia & Upjohn Spa Derivatives of aryl and heteroaryl purine
FR2741881B1 (fr) * 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques

Also Published As

Publication number Publication date
DE69733674D1 (de) 2005-08-04
HK1020884A1 (en) 2000-05-26
PL331408A1 (en) 1999-07-19
DE69733674T2 (de) 2006-05-04
PT1021186E (pt) 2005-11-30
ATE298572T1 (de) 2005-07-15
RU2220968C2 (ru) 2004-01-10
NO990466L (no) 1999-03-25
AU3900097A (en) 1998-02-25
ES2242981T3 (es) 2005-11-16
AU731778B2 (en) 2001-04-05
GEP20022786B (en) 2002-09-25
CZ299381B6 (cs) 2008-07-09
CN1231611A (zh) 1999-10-13
NO990466D0 (no) 1999-02-01
EP1021186A1 (en) 2000-07-26
KR100403336B1 (ko) 2003-10-30
CA2262454A1 (en) 1998-02-12
EP1021186A4 (en) 2000-07-26
PL189775B1 (pl) 2005-09-30
NZ334061A (en) 2000-08-25
US5866702A (en) 1999-02-02
JP2000515550A (ja) 2000-11-21
IL128323A (en) 2001-11-25
CZ33899A3 (cs) 2000-03-15
EP1021186B1 (en) 2005-06-29
NO323775B1 (no) 2007-07-02
WO1998005335A1 (en) 1998-02-12
HUP9902414A2 (hu) 2001-04-28
CN1161356C (zh) 2004-08-11
DK1021186T3 (da) 2005-10-17
UA71890C2 (en) 2005-01-17
CA2262454C (en) 2006-02-07
KR20000029781A (ko) 2000-05-25
IL128323A0 (en) 2000-01-31
BR9710801A (pt) 2001-11-27
HUP9902414A3 (en) 2002-04-29
TR199900683T2 (xx) 2002-01-21

Similar Documents

Publication Publication Date Title
IL128323A0 (en) Purine inhibitors of cyclin dependent kinase 2
NZ513402A (en) Novel nucleosides and oligonucleotide analogues
TR200102714T2 (tr) Sikline bağımlı kinaz 2 ve IkB-&'nın pürün inhibitörleri
DE69002739D1 (de) Reduzierende zusammensetzung zur dauerhaften haarverformung, die als reduzierendes agens ein aminomercaptoalkylamid oder eines seiner salze enthaelt sowie ihre verwendung in einem verfahren zur dauerhaften haarverformung.
BG102349A (en) Pyrazolopyrimidines as crf receptor antagonists
AU8680291A (en) An aminoglycoside composition having substantially reduced nephrotoxicity induced by the amino glycoside
GR3036173T3 (en) Purified form of streptogramines, preparation of same and pharmaceutical compositions containing same
GB2143232B (en) Chemical compounds
EP0371139A4 (en) 6-substituted acyclicpyrimidine nucleoside derivatives and antiviral agents containing same as active ingredients
AU3135889A (en) Benzophenone derivatives
DE69801594D1 (de) Kosmetische zusammensetzung enthaltend eine indigotyp-verbindung
CS548483A2 (en) Zpusob vyroby muramylpeptidu
GR3003738T3 (Direct)
WO1999035912A8 (en) Tuberculocidal disinfectant
ZA934576B (en) 4-iminoquinolines processes for their preparation and their use
KR910000710A (ko) 멸균제 누클레오시드류
IL77583A (en) N-sulphonyl-n'-phosphonomethyl glycine derivatives,process for the preparation thereof and herbicidal compositions comprising the same
AU644085B2 (en) Antiherpes pentapeptides
EP0150822A3 (en) Oximinophosphoric acid derivatives, process for their preparation and their use as pesticides
DE3275083D1 (en) Cycloaliphatic alcohols